Botanix Pharmaceuticals Limited (BXPHF)
- Previous Close
0.1300 - Open
0.0085 - Bid --
- Ask --
- Day's Range
0.0085 - 0.0085 - 52 Week Range
0.0085 - 0.4800 - Volume
2,000 - Avg. Volume
2,470 - Market Cap (intraday)
14.921M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.
www.botanixpharma.comRecent News: BXPHF
Performance Overview: BXPHF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BXPHF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BXPHF
Valuation Measures
Market Cap
227.25M
Enterprise Value
221.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.97k
Price/Book (mrq)
7.04
Enterprise Value/Revenue
2.39k
Enterprise Value/EBITDA
-22.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.33%
Return on Equity (ttm)
-32.25%
Revenue (ttm)
437.21k
Net Income Avi to Common (ttm)
-10.02M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
18.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-22.12M